Proteocyte Diagnostics Inc., a company with a unique test for early identification of oral cancers, today announced their selection as a semi-finalist of the National Angel Capital Organization (NACO) 2014 Pitch competition.
“We’re excited to be a semi-finalist in the NACO competition,” said Dr. Mario Thomas, President of Proteocyte Diagnostics. “We appreciate being recognized as one of Canada’s most promising startups. This reinforces our belief that, by identifying cancer before it happens, Straticyte will have a significant social impact by saving lives, increasing quality of life, reducing healthcare costs and deliver a strong financial return to investors.”
Proteocyte Diagnostics is a Canadian molecular diagnostics company that has developed a novel diagnostics test, Straticyte™ that objectively and accurately detects precancerous oral lesions at high risk of becoming cancerous. Straticyte is the first and only molecular diagnostic test for oral precancerous lesions that provides an objective and accurate prediction score as evidenced by retrospective clinical studies.
NACO is a non-profit organization that promotes and helps create a vibrant Angel community in Canada. NACO’s annual Pitch Competition celebrates dynamic early-stage companies that have demonstrated successful growth and whose outstanding achievements have made them some of Canada’s most promising startups. Up to 15 semi-finalists will be invited to attend the 2014 National Angel Summit and will vie to be one of the five (5) finalists to pitch on stage to over 200 Angel investors, venture capitalists and industry leaders. The winner will be selected by an expert panel of judges and audience voting and be crowned as NACO’s Most Promising Startup of the Year, presented by KPMG Enterprise. The 2014 Pitch Competition will take place in Quebec City, on Thursday, October 2, during the 2014 National Angel Summit (October 1-3).
About Proteocyte Diagnostics
Proteocyte Diagnostics Inc. is a Canadian molecular diagnostics company that develops and commercializes a novel diagnostics technology, Straticyte™ that offers objective and accurate early diagnosis of precancers and cancers. The company’s first product objectively and accurately distinguishes between those precancerous oral lesions at high risk of becoming cancerous and those that pose low risk. Early diagnosis of high risk lesions permits more effective and less traumatizing treatments. By identifying and treating oral cancer before it happens, clinicians can save lives, healthcare costs are reduced and quality of life of patients is improved. Identifying more accurately low risk pre-cancerous lesions avoids unnecessary surgeries and allows clinicians to monitor patients regularly for peace of mind.
Media contacts:
Proteocyte Diagnostics Inc.
Leslie Caton
Communications Manager
416-994-4051
lcaton@proteocyte.com